Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Sells China Rights for IDH1 Inhibitor to Servier Pharma for $50 Million

publication date: Dec 21, 2023

Suzhou CStone Pharma sold China-Singapore commercialization rights for Tibsovo® (ivosidenib tablets) to Servier of Paris for $50 million. CStone originally acquired the China rights to the drug from Agios Pharmaceuticals, which subsequently became part of Servier. Tibsovo is an oral targeted IDH1 inhibitor that is approved in China to treat adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation. CStone said the sale would save paying additional milestones while it recouped its investment. In 2018, CStone in-licensed the rights in a $424 million deal, though it paid only $12 million upfront plus plus $147 million in milestones. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital